With the deepening of the study of tumor pathogenesis, tumor immunotherapy has become the most promising treatment mode at present, providing new treatment options for patients. However, the current research on various response modes of immunotherapy is not thorough enough, and the development and use of immunotherapy still need to be further optimized.
As one of the important activities of the Zhangjiang Life Science International Innovation Summit Global Dialogue Forum, "tumor immunotherapy" became a hot topic during the "Zhangjiang Innovative Drug Frontier Technology Forum" co-hosted by Shanghai Zhangjiang Biomedical Base Development Co., Ltd., Shanghai Innostar Biotechnology Co., Ltd. and Shanghai Zhangjiang Innovative Drug Industry Base Construction Co., Ltd.
The conference invited Academician Ding Jian of the Chinese Academy of Engineering as the chairman of the conference, bringing together industry leaders in the field of cutting-edge technology. The forum set up a total of 3 special sessions, including conjugate drugs, nucleic acid and delivery, and the Zhangjiang layout of the global future industry, etc., sharing the research progress of hot frontier technologies in the form of keynote speeches and roundtable discussions, colliding with sparks of thinking, and promoting innovation and development.
Immuno-oncology requires a deeper understanding
At the scene, Academician Ding Jian brought the keynote report of "Opportunities and Challenges of Tumor Immunotherapy", Academician Ding pointed out that the current tumor immunotherapy represented by immune checkpoint inhibitors has become a new strategy for tumor treatment. He elaborated on the opportunities and challenges encountered in tumor immunotherapy, including the construction of immune characteristics of preclinical tumor models, the clinical efficacy is not ideal, especially the immune escape caused by multi-factor and multi-link. Based on this, combination drugs are still the general trend of tumor immunotherapy, that is, a combination of various immunotherapy strategies is adopted to fight tumors.
"Up to now, the State Medical Products Administration has approved 13 PD-1/PD-L1 products, 9 of which are made in China and 4 are imported." Compared with the PD-1/PD-L1 target cluster and fierce competition, Academician Ding believes that bi-antibody, tertiary antibody and small molecule immunosuppressant are the trend of immunotherapy in the future, and tumor immunotherapy needs to be more deeply understood, and it is expected that breakthroughs in basic research can bring a new starting point.
The reporter learned from the meeting that China and the United States dominate the development of cell immunotherapy, of which CAR-T technology accounts for the highest proportion of cell therapy and the fastest growth rate. Up to now, a total of 8 cell therapy products have been launched in the world, including 6 in the United States and 2 in China. It is worth mentioning that these two cell therapy products in China are from Zhangjiang.
Explore the linkage mechanism of joint review during and after the event based on regulatory science
At the end of 2020, the Yangtze River Delta Branch Center of Drug Evaluation and Inspection of the State Food and Drug Administration and the Yangtze River Delta Branch Center of Medical Device Technical Evaluation and Inspection landed in Zhangjiang. Thanks to the "zero distance" of drug review, the clinical application of new drugs and new medical devices of innovative drug companies has accelerated.
At the conference, Yang Jinbo, director of the Yangtze River Delta Sub-center of Drug Evaluation and Inspection of the State Food and Drug Administration, delivered a keynote speech on "Exploring New Mechanisms for Research and Review Linkage to Promote Biomedical Innovation in the Yangtze River Delta", and the report focused on the drug review overview of the Yangtze River Delta Sub-center of the State Food and Drug Administration and explored a new mechanism for research and review linkage.
He said that at present, the Yangtze River Delta sub-center is deeply involved in the review of IND and NDA applications for innovative drugs in the region, establishing a service mechanism for key projects in the region, and will further explore the linkage mechanism of joint review during and after the event based on regulatory science in the future. "Since our sub-center settled in Shanghai, through active participation, coordination and promotion, the speed of R&D and approval of innovative drugs in the Yangtze River Delta region has been accelerating. In terms of service quality improvement, we discuss new technologies, new methods and new standards with industry experts and enterprise scientists, and then use them as the basis for our decision-making, and finally become our guide. ”
In addition, the forum focused on the new concept of conjugate drug track, and Cang Yong, professor of ShanghaiTech University and founder of Dage Biologics, Chen Zhaorong, CEO of Yuhe Pharmaceutical, and Xu Ming, CEO of Aboz Pharmaceutical, shared new technologies and new directions of the coupling road from different directions such as molecular glue drugs, antibody conjugate drugs, and molecular targeted nuclear drugs.
At the special session of "Technical Innovation of Nucleic Acids and Delivery" hosted by Dr. Chang Yan, President of Innos, various innovative enterprises and leading enterprises shared the latest progress in the field of cell therapy.
Responsible Editor: Liqi Ni
Text Yang Zhenying
Source: Pudong Release